NCT04100187View on ClinicalTrials.gov

Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia

PHASE1UnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

August 1, 2023

Study Completion Date

August 1, 2024

Conditions
Leukemia
Interventions
BIOLOGICAL

Anti-CD19-CAR

Cells extracted, followed by induction chemotherapy before CD19-CAR infusion (dose escalation.)

Sponsors
All Listed Sponsors
collaborator

Hebei Yanda Ludaopei Hospital

OTHER

lead

Kecellitics Biotech Company Ltd

INDUSTRY

NCT04100187 - Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia | Biotech Hunter | Biotech Hunter